FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2488254673> ?p ?o ?g. }

• W2488254673 endingPage "22" @default.
• W2488254673 startingPage "18" @default.
• W2488254673 abstract "Objective Platinum-based doublet chemotherapy is the standard for most patients with advanced non-small cell lung cancer (NSCLC). Toxicity concerns limit chemotherapy for patients over 70 years. Vinorelbine and paclitaxel are effective as single agents in advanced NSCLC. This phase II study evaluates safety and efficacy of a combination of these two agents in patients >70 years with advanced NSCLC. Materials and Methods Patients with treatment naïve metastatic NSCLC received two cycles comprising 6 weekly doses of vinorelbine and paclitaxel, with restaging scans at week 8. Patients with radiographic progression came off study. The estimated sample size was 29. Toxicity analyses were conducted after 10 patients and again after 19 patients were enrolled. Outcomes were safety and efficacy, progression free (PFS) and overall survival (OS) and quality of life (QOL). Results The study closed at second interim analysis as 6/19 patients had ≥grade 4 non-hematologic toxicity (respiratory failure, sepsis, ischemic encephalopathy, pneumonia, hypoxemia, cardiopulmonary arrest, neutropenic fever, death). Of the 16 evaluable patients, 7 completed the study. Disease control rate (partial response + stable disease) was 47% (n = 9); 37% (n = 7) progressed. No complete responses were seen. Median PFS was 3.5 months (95% CI: 1.4, 5.5) and OS 7.8 months (95% CI: 1.9, 13.6). QOL did not change compared to baseline, at week 9, but increased at week 17. Conclusions Although the combination met its response end points, increased toxicity makes this combination unsuitable for older patients. While QOL improved over the study, the small sample hinders interpretation." @default.
• W2488254673 created "2016-08-23" @default.
• W2488254673 creator A5005272274 @default.
• W2488254673 creator A5024497224 @default.
• W2488254673 creator A5033453495 @default.
• W2488254673 creator A5051802695 @default.
• W2488254673 creator A5052640163 @default.
• W2488254673 creator A5056695976 @default.
• W2488254673 creator A5057029809 @default.
• W2488254673 creator A5065113476 @default.
• W2488254673 creator A5066299608 @default.
• W2488254673 creator A5072808304 @default.
• W2488254673 creator A5081261667 @default.
• W2488254673 creator A5088813879 @default.
• W2488254673 creator A5091831303 @default.
• W2488254673 date "2017-01-01" @default.
• W2488254673 modified "2023-10-16" @default.
• W2488254673 title "Weekly vinorelbine and paclitaxel in older patients with advanced non-small cell lung cancer: A phase II Fred and Pamela Buffet Cancer Center Clinical Trials Network study" @default.
• W2488254673 cites W1496563114 @default.
• W2488254673 cites W1898736255 @default.
• W2488254673 cites W1976879961 @default.
• W2488254673 cites W1978072892 @default.
• W2488254673 cites W1985722827 @default.
• W2488254673 cites W1993199137 @default.
• W2488254673 cites W2037139573 @default.
• W2488254673 cites W2065731961 @default.
• W2488254673 cites W2079315759 @default.
• W2488254673 cites W2085082111 @default.
• W2488254673 cites W2121095198 @default.
• W2488254673 cites W2128082578 @default.
• W2488254673 cites W2137009016 @default.
• W2488254673 cites W2151986118 @default.
• W2488254673 cites W2164778107 @default.
• W2488254673 cites W2336898992 @default.
• W2488254673 doi "https://doi.org/10.1016/j.jgo.2016.07.006" @default.
• W2488254673 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/27491498" @default.
• W2488254673 hasPublicationYear "2017" @default.
• W2488254673 type Work @default.
• W2488254673 sameAs 2488254673 @default.
• W2488254673 citedByCount "8" @default.
• W2488254673 countsByYear W24882546732017 @default.
• W2488254673 countsByYear W24882546732018 @default.
• W2488254673 countsByYear W24882546732020 @default.
• W2488254673 countsByYear W24882546732021 @default.
• W2488254673 countsByYear W24882546732022 @default.
• W2488254673 countsByYear W24882546732023 @default.
• W2488254673 crossrefType "journal-article" @default.
• W2488254673 hasAuthorship W2488254673A5005272274 @default.
• W2488254673 hasAuthorship W2488254673A5024497224 @default.
• W2488254673 hasAuthorship W2488254673A5033453495 @default.
• W2488254673 hasAuthorship W2488254673A5051802695 @default.
• W2488254673 hasAuthorship W2488254673A5052640163 @default.
• W2488254673 hasAuthorship W2488254673A5056695976 @default.
• W2488254673 hasAuthorship W2488254673A5057029809 @default.
• W2488254673 hasAuthorship W2488254673A5065113476 @default.
• W2488254673 hasAuthorship W2488254673A5066299608 @default.
• W2488254673 hasAuthorship W2488254673A5072808304 @default.
• W2488254673 hasAuthorship W2488254673A5081261667 @default.
• W2488254673 hasAuthorship W2488254673A5088813879 @default.
• W2488254673 hasAuthorship W2488254673A5091831303 @default.
• W2488254673 hasConcept C121608353 @default.
• W2488254673 hasConcept C126322002 @default.
• W2488254673 hasConcept C141071460 @default.
• W2488254673 hasConcept C143998085 @default.
• W2488254673 hasConcept C2776256026 @default.
• W2488254673 hasConcept C2776694085 @default.
• W2488254673 hasConcept C2777063308 @default.
• W2488254673 hasConcept C2777511904 @default.
• W2488254673 hasConcept C2778239845 @default.
• W2488254673 hasConcept C2778336483 @default.
• W2488254673 hasConcept C2778850193 @default.
• W2488254673 hasConcept C2780350996 @default.
• W2488254673 hasConcept C2781413609 @default.
• W2488254673 hasConcept C29730261 @default.
• W2488254673 hasConcept C530470458 @default.
• W2488254673 hasConcept C535046627 @default.
• W2488254673 hasConcept C61943457 @default.
• W2488254673 hasConcept C71924100 @default.
• W2488254673 hasConceptScore W2488254673C121608353 @default.
• W2488254673 hasConceptScore W2488254673C126322002 @default.
• W2488254673 hasConceptScore W2488254673C141071460 @default.
• W2488254673 hasConceptScore W2488254673C143998085 @default.
• W2488254673 hasConceptScore W2488254673C2776256026 @default.
• W2488254673 hasConceptScore W2488254673C2776694085 @default.
• W2488254673 hasConceptScore W2488254673C2777063308 @default.
• W2488254673 hasConceptScore W2488254673C2777511904 @default.
• W2488254673 hasConceptScore W2488254673C2778239845 @default.
• W2488254673 hasConceptScore W2488254673C2778336483 @default.
• W2488254673 hasConceptScore W2488254673C2778850193 @default.
• W2488254673 hasConceptScore W2488254673C2780350996 @default.
• W2488254673 hasConceptScore W2488254673C2781413609 @default.
• W2488254673 hasConceptScore W2488254673C29730261 @default.
• W2488254673 hasConceptScore W2488254673C530470458 @default.
• W2488254673 hasConceptScore W2488254673C535046627 @default.
• W2488254673 hasConceptScore W2488254673C61943457 @default.
• W2488254673 hasConceptScore W2488254673C71924100 @default.
• W2488254673 hasIssue "1" @default.
• W2488254673 hasLocation W24882546731 @default.

• next